Interestingly, there are already ongoing clinical trials performed with several AURKA (NCT00249301, NCT01924260) and STAT3 (NCT02983578, NCT03382340) inhibitors with pancreatic cancer patients (https://clinicaltrials.gov (accessed on 5 January 2021)), further supporting the relevance of the model’s conclusions. Here, STAT3 is linked to pancreatic neoplasm.